SAN DIEGO / Aug 28, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside Chat: Wednesday, September 4, 2024 at 4:50 p.m. Eastern Time in New York, NY
Baird 2024 Global Healthcare Conference
Fireside Chat: Wednesday, September 11, 2024 at 9:40 a.m. Eastern Time in New York, NY
Live webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.
| Last Trade: | US$16.61 |
| Daily Change: | -0.34 -2.01 |
| Daily Volume: | 105,812 |
| Market Cap: | US$2.760B |
December 19, 2024 December 09, 2024 November 26, 2024 November 06, 2024 October 16, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
